

## DAFTAR PUSTAKA

1. Kang JM, Tanna AP. Glaucoma. *Medical Clinics of North America*. 2021 May 1;105(3):493–510.
2. Rapuano CJ, Stout JT, McCannel CA. 2021–2022 Basic and Clinical Science Course (BCSC), Section 10: Glaucoma. San Fransisco: American Academy of Ophthalmology; 2021.
3. Salmon JF. Glaucoma. In: Riordan-Eva P, Augsburger JJ, editors. *Vaughan & Asbury's General Ophthalmology*. 19th ed. New York: McGraw-Hill Education LLC; 2018. p. 518–54.
4. Ilyas S, Yulianti SR. *Ilmu Penyakit Mata*. 5th ed. Jakarta: FK UI; 2014.
5. Bourne RRA, Steinmetz JD, Saylan M, Mersha AM, Weldemariam AH, Wondmeneh TG, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. *Lancet Glob Health*. 2021 Feb 1;9(2):144–60.
6. Allison K, Patel D, Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. *Cureus*. 2020 Nov 24;12(11):1–9.
7. Rif'Ati L, Halim A, Lestari YD, Moeloek NF, Limburg H. Blindness and Visual Impairment Situation in Indonesia Based on Rapid Assessment of Avoidable Blindness Surveys in 15 Provinces. *Ophthalmic Epidemiol*. 2021;28(5):408–19.
8. Kementerian Kesehatan RI. *InfoDatin: Situasi Glaukoma di Indonesia*. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI; 2019. p. 1–11.
9. Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying 'target' intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. *Indian J Ophthalmol*. 2018 Apr 1;66(4):495–505.
10. Dietze J, Blair K, Havens SJ. Glaucoma. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2023 Oct 30]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538217/>
11. Lusthaus J, Goldberg I. Current management of glaucoma. *Medical Journal of Australia*. 2019 Mar 1;210(4):180–7.
12. Cvenkel B, Kolko M. Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment. *J Ophthalmol*. 2020 Jul 21;2020:1–14.
13. Schuster AK, Erb C, Hoffmann EM, Dietlein T, Pfeiffer N. The diagnosis and treatment of glaucoma. *Dtsch Arztebl Int*. 2020 Mar 27;117(13):225–34.

14. Guglielmi P, Carradori S, Campestre C, Poce G. Novel therapies for glaucoma: a patent review (2013-2019). *Expert Opin Ther Pat.* 2019 Oct 3;29(10):769–80.
15. Hulandari R. Profil Pasien Glaukoma di Poliklinik Mata RSUP Dr. M. Djamil Padang Tahun 2016 [Skripsi]. Universitas Andalas; 2018.
16. Nurulkhairani SS, Riasari V, Suzan R, Mayani G, Karolina ME. Gambaran Perbaikan Tekanan Intraokular pada Pasien yang Telah Diterapi di RSUD H. Abdul Manap Jambi Tahun 2019-2021. *JOMS.* 2023;3(1):11–21.
17. Joh HJ, Jin SW. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series. *Jpn J Ophthalmol.* 2019 Jul 12;63(4):322–7.
18. Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019. *Expert Opin Ther Pat.* 2019 Oct 3;29(10):781–92.
19. Netland PA, Tanna AP, editors. *Glaucoma medical therapy: principles and management.* 3rd ed. Amsterdam: Kugler Publications; 2021.
20. Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern®. *Ophthalmology.* 2021 Jan 1;128(1):71–150.
21. Wang T, Cao L, Jiang Q, Zhang T. Topical Medication Therapy for Glaucoma and Ocular Hypertension. *Front Pharmacol.* 2021 Dec 1;12:1–30.
22. Praba VM, Primitasari Y, Qorib MF, Loebis R. Selection of Medical Therapy in Glaucoma Patients in the Outpatient Eye Clinic Soetomo General Academic Hospital Surabaya. *Folia Medica Indonesiana.* 2021 Dec 4;57(4):324–33.
23. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1488/2023 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Glaukoma. 2023.
24. Perdami. Pedoman Nasional Pelayanan Kedokteran Glaukoma. 2018.
25. Murni RM. Analisis Faktor Penyebab Pending Claim Rawat Inap Pasien Jaminan Kesehatan Nasional (JKN) di RSUP Dr. M. Djamil Padang Bulan Januari – Juni Tahun 2022 [Tesis]. Universitas Andalas; 2023.

26. Nabilah T, Dewi NMAR, Aini SR. Evaluasi kesesuaian peresepan obat terhadap formularium nasional di Rumah Sakit Umum Daerah Sumbawa tahun 2021. *Sasambo Journal of Pharmacy*. 2023 Apr 30;4(1):14–8.
27. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/2197/2023 tentang Formularium Nasional. 2023.
28. Kementerian Kesehatan RI. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/200/2020 tentang Pedoman Penyusunan Formularium Rumah Sakit. 2020.
29. Shalaby WS, Shankar V, Razeghinejad R, Katz LJ. Current and new pharmacotherapeutic approaches for glaucoma. *Expert Opin Pharmacother*. 2020 Nov 1;21(16):2027–40.
30. Anggriani A, Utami P, Lisni I. Kajian Potensi Interaksi Obat Pada Pasien Glaukoma di Salah Satu Rumah Sakit di Bandung. *Jurnal Sains dan Kesehatan*. 2016;1(5):226–35.
31. Mustofa A, Mas Ulfa N, Suryandari M. Profil Peresepan Penyakit Mata Glaukoma pada Pasien BPJS Rawat Jalan. *Journal of Pharmacy and Science*. 2016 Jul;1(1):27–33.
32. Angriani N, Akib MNR, Mulyadi FE, Irmandha S, Hadi S, Syamsu RF. Glaucoma risk factors. *Green Medical Journal*. 2022 Apr 30;4(1):1–8.
33. Khachatryan N, Pistilli M, Maguire MG, Salowe RJ, Fertig RM, Moore T, et al. Primary Open-Angle African American Glaucoma Genetics (POAAGG) Study: gender and risk of POAG in African Americans. *PLoS One*. 2019 Aug 1;14(8):1–11.
34. Gedde SJ, Chen PP, Muir KW, Vinod K, Lind JT, Wright MM, et al. Primary Angle-Closure Disease Preferred Practice Pattern®. *Ophthalmology*. 2021 Jan 1;128(1):30–70.
35. Machiele R, Motlagh M, Patel BC. Intraocular pressure. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2023 Oct 20]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK532237/>
36. Salmon JF. Glaucoma. In: Kanski's Clinical Ophthalmology: A Systematic Approach. 9th ed. Amsterdam: Elsevier; 2020. p. 345–422.
37. Sharaawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. *Glaucoma: Medical Diagnosis & Therapy*. 2nd ed. Vol. 1. Elsevier Saunders; 2015.

38. Evangelho K, Mogilevskaya M, Losada-Barragan M, Vargas-Sanchez JK. Pathophysiology of primary open-angle glaucoma from a neuroinflammatory and neurotoxicity perspective: a review of the literature. *Int Ophthalmol*. 2017 Jan 15;39(1):259–71.
39. Sun X, Dai Y, Chen Y, Yu DY, Cringle SJ, Chen J, et al. Primary angle closure glaucoma: What we know and what we don't know. *Prog Retin Eye Res*. 2017 Mar 1;57:26–45.
40. Killer HE, Pircher A. Normal tension glaucoma: review of current understanding and mechanisms of the pathogenesis. *Eye*. 2018 May;32(5):924–30.
41. Kaur K, Gurnani B. Primary Congenital Glaucoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Oct 23]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK574553/>
42. Momont AC, Kaufman PL. Medical Therapy for Glaucoma-IOP Lowering Agents. In: Sun X, Dai Y, editors. *Medical Treatment of Glaucoma*. Singapore: Springer Singapore; 2019. p. 115–35.
43. Katzung Bertram G., Vanderah Todd W. *Basic & Clinical Pharmacology*. 15th ed. New York: McGraw-Hill; 2020.
44. Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. *Front Pharmacol*. 2022 Oct 12;13:1–9.
45. Tang W, Zhang F, Liu K, Duan X. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis. *Medicine*. 2019 Jul;98(30):1–10.
46. Gunawan SG, Setiabudy R, Nafrialdi, Instiaty, editors. *Farmakologi dan Terapi*. 6th ed. Jakarta: Badan Penerbit FKUI; 2016.
47. Ghorai S, Pulya S, Ghosh K, Panda P, Ghosh B, Gayen S. Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. *Bioorg Chem*. 2020 Jan;95:1–34.
48. Masini E, Sgambellone S, Lucarini L. Carbonic anhydrase inhibitors as ophthalmologic drugs for the treatment of glaucoma. In: Supuran CT, Nocentini A, editors. *Carbonic Anhydrases*. Academic Press; 2019. p. 269–85.
49. Nocentini A, Supuran CT. Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013–2019). *Expert Opin Ther Pat*. 2019 Oct 3;29(10):805–15.



50. Cimolai N. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. *Hum Exp Toxicol*. 2020 Apr 29;39(10):1279–90.
51. Sostroasmoro S, Ismael S, editors. *Dasar-dasar Metodologi Penelitian Klinis*. 5th ed. Jakarta: Sagung Seto; 2014.
52. Marx-Gross S, Laubert-Reh D, Schneider A, Höhn R, Mirshahi A, Münzel T, et al. The Prevalence of Glaucoma in Young People. *Dtsch Arztebl Int*. 2017 Mar 24;114(12):204–10.
53. Dizayang F, Bambang H, Purwoko M. Karakteristik Penderita Glaukoma di Rumah Sakit Muhammadiyah Palembang Periode Januari 2017-April 2018. *Journal of Health Sciences*. 2020 Feb 5;13(01):66–73.
54. Nelson-Ayifah D, Mashige KP. Demographic and clinical characteristics of patients with glaucoma in a tertiary eye facility in Ghana. *African Vision and Eye Health*. 2020;79(1):1–6.
55. Jammal AA, Berchuck SI, Thompson AC, Costa VP, Medeiros FA. The effect of age on increasing susceptibility to retinal nerve fiber layer loss in glaucoma. *Invest Ophthalmol Vis Sci*. 2020 Nov 5;61(13).
56. McMonnies CW. Historial de glaucoma y factores de riesgo. *J Optom*. 2017 Apr 1;10(2):71–8.
57. Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. *Sci Rep*. 2021 Dec 1;11(1).
58. Arman AD. Karakteristik Penderita Glaukoma di Rumah Sakit Mata Makassar Periode 2022 [Skripsi]. Universitas Bosowa; 2023.
59. Arrahman IH. Hubungan Visual Field Index dengan Stadium Primary Open Angle Glaucoma di RSUP Dr. M. Djamil pada Tahun 2017-2019 [Skripsi]. Universitas Andalas; 2021.
60. Sari HV. Profil Pasien Glaukoma Juveinil di Poliklinik Mata RS Dr M. Djamil Padang Tahun 2017-2020 [Skripsi]. Universitas Andalas; 2021.
61. Kurnia NS. Hubungan Visual Acuity dengan Stadium Primary Angle Closure Glaucoma di Poliklinik Mata RSUP Dr. M. Djamil Padang [Skripsi]. Universitas Andalas; 2022.
62. Lee SSY, Mackey DA. Glaucoma – risk factors and current challenges in the diagnosis of a leading cause of visual impairment. *Maturitas*. 2022 Nov;163:15–22.

63. Sari GP. Hubungan Tekanan Darah dengan Tekanan Intraokular pada Pasien Glaukoma Primer Sudut Terbuka di RSUP Dr. M. Djamil Padang pada Periode Januari 2017 – Desember 2018 [Skripsi]. Universitas Andalas; 2020.
64. Alfisyahrin N, Feriyani. Gambaran Variasi Terapi Glaukoma Pada Penderita Glaukoma di RSUD Meuraxa. *Jurnal Sains Riset*. 2021;11(2):288–93.
65. Harasymowycz P, Birt C, Gooi P, Heckler L, Hutnik C, Jinapriya D, et al. Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. Vol. 2016, *Journal of Ophthalmology*. Hindawi Publishing Corporation; 2016.
66. Mittal S, Mittal D. Long Term Glaucoma Therapy Trend in India. *Scholars Journal of Applied Medical Sciences*. 2021 Jan 5;9(1):33–7.
67. Shaifali I, Gupta N, Chandra S, Agarwal K. A comparative study on the efficacy and cost-effectiveness of latanoprost and timolol in glaucoma. *Natl J Physiol Pharm Pharmacol*. 2020;(0):1.
68. Shirai C, Matsuoka N, Nakazawa T. Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study. *BMC Ophthalmol*. 2021 Dec 1;21(1).
69. Tejwani S, Machiraju P, Nair AP, Ghosh A, Das RK, Ghosh A, et al. Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork. *J Cell Mol Med*. 2020 May 1;24(9):5195–204.
70. Lerner SF, Oddone F, Lu DW, Sanseau A, Guarro M, Ridolfi A, et al. Maximum medical therapy: Brinzolamide/brimonidine and travoprost/timolol fixed-dose combinations in glaucoma and ocular hypertension. *Clinical Ophthalmology*. 2019;13:2411–9.
71. Gulati S, Aref AA. Oral acetazolamide for intraocular pressure lowering: balancing efficacy and safety in ophthalmic practice. *Expert Rev Clin Pharmacol*. 2021;14(8):955–61.
72. Wagner I V., Stewart MW, Dorairaj SK. Updates on the diagnosis and management of glaucoma. *Mayo Clin Proc Innov Qual Outcomes*. 2022 Dec;6(6):618–35.
73. Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: A pharmacokinetic perspective. Vol. 10, *Clinical Ophthalmology*. Dove Medical Press Ltd; 2016. p. 2433–41.

74. Ofei-Palm CNK, Tagoe NN, Jatoe D, Agyare A, Ankrah D. Cost analysis and rational use of anti-glaucoma therapy in a tertiary hospital in Ghana. *ClinicoEconomics and Outcomes Research*. 2021;13:619–27.
75. Arbabi A, Bao X, Shalaby WS, Razeghinejad R. Systemic side effects of glaucoma medications. Vol. 105, *Clinical and Experimental Optometry*. Taylor and Francis Ltd.; 2022. p. 157–65.
76. Lindén C, Heijl A, Jóhannesson G, Aspberg J, Andersson Geimer S, Bengtsson B. Initial intraocular pressure reduction by mono-versus multi-therapy in patients with open-angle glaucoma: results from the Glaucoma Intensive Treatment Study. *Acta Ophthalmol*. 2018 Sep 1;96(6):567–72.
77. Powell S, Doolan E, Curtin K, Doyle A, O'Brien C. Audit of outcomes following attendance at the City West drive-through IOP glaucoma clinic during the COVID-19 pandemic. *Ir J Med Sci*. 2022 Dec 1;191(6):2813–22.

